API | vatalanib

vatalanib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Vatalanib is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, which is to say it is effective when taken by mouth. ^Wikipedia

Chemistry

SMILES: Clc1ccc(Nc2nnc(Cc3ccncc3)c4ccccc24)cc1
InChIKey: YCOYDOIWSSHVCK-UHFFFAOYSA-N
Mol. Mass: 346.82
ALogP: 5.01 Partition coefficient
ChEMBL Molecule:
vatalanib

More Chemistry

Pharmacology

Mechanisms of Action:
- Macrophage colony-stimulating factor 1 receptor (Homo sapiens) ^UniProt
- Platelet-derived growth factor receptor alpha (Homo sapiens) ^UniProt
- Platelet-derived growth factor receptor beta (Homo sapiens) ^UniProt
- Mast/stem cell growth factor receptor Kit (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate | 1-(4-chloroanilino)-4-(pyridylmethyl)phthalazine | 1-(4-chloroanilino)-(4-pyridylmethyl)phthalazine dihydrochloride | 1-(4-chloroanilino)-4-(pyridylmethyl)phthalazine dihydrochloride | bay-86-5127 | cgp-79787 | cgp 797870 | cgp-797870 | k-222584 | nvp-ptk787 | ptk787 | ptk 787 | ptk-787 | ptk/zk | vatalanib | vatalinib | zk222584 | zk 222584 | zk-222584 | zk232934 | zk 232934 | zk-232934

Organizations (38)

Research & Development (38)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (46)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (46)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Islet Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Colonic Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 3)

Endometrial Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 1)

Gastrinoma (Phase 1)

Glioblastoma (Phase 1)

Glucagonoma (Phase 1)

Hamartoma (Phase 1)

Healthy Volunteers (Phase 1)

Insulinoma (Phase 1)

Intestinal Neoplasms (Phase 2)

Kidney Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Lymphoma (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Melanoma (Phase 2)

Mesothelioma (Phase 1/Phase 2)

Mesothelioma, Malignant (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 1)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Pheochromocytoma (Phase 1)

Primary Myelofibrosis (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 3)

Retinal Diseases (Phase 2)

Sarcoma (Phase 2)

Somatostatinoma (Phase 1)

Squamous Intraepithelial Lesions (Phase 2)

Thyroid Neoplasms (Phase 1)

Uterine Cervical Neoplasms (Phase 2)

von Hippel-Lindau Disease (Phase 2)

Wet Macular Degeneration (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 46
# of Trial Organizations: 38

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue